Elafibranor

- Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi® to be Presented atThe Liver Meeting® 2025 - - New Three-Year Interim Data Demonstrates Livdelzi® May Help Stabilize or Improve Liver Health in PBC Patients - FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and viral hepatitis will include late-breaking data and three oral presentations. Primary Biliary Cholangitis Research Three late-breaking presentations will share new data on Livdelzi® (seladelpar) in people living with primary biliary cholangitis (PBC), including real-world treatment experience following the withdrawal of obeticholic acid (LB#5037), liver stiffness outcomes from a three-year interim analysis of the ongoing ASSURE study (LB#5031), and long-term pruritus data from the RESPONSE trial and its open-label extension (#LB5015). These studies explore how Livdelzi is being used in clinical practice, its potential impact on liver health, and patient-reported experiences with itch over time. “The data we’re sharing at The Liver Meeting® reflect our continued dedication to advancing science that meaningfully improves the lives of people affected by liver disease,” said Anu Osinusi, Vice President, Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead. “These interim long-term findings in PBC deepen our understanding of disease progression and highlight the potential to help improve patients’ liver health and symptoms.” Viral Hepatitis Research Gilead also plans to share new data from across its viral hepatitis portfolio. In hepatitis delta virus (HDV), Gilead will present integrated analyses from the MYR204 (NCT03852433) and MYR301 (NCT03852719) studies, investigating the long-term safety and efficacy of bulevirtide for the treatment of chronic HDV. Gilead will also present an analysis from the Phase 3 ALLIANCE study (NCT03547908) that aims to study HIV/HBV co-infected participants who achieved hepatitis B virus surface antigen (HBsAg) loss, a marker of HBV functional cure, after starting tenofovir-based treatments. Lastly, data from a Phase 1b study on the safety, tolerability and antiviral efficacy of GS-2829 and GS-6779, novel investigational therapeutic HBV vaccines, among virally suppressed participants with chronic hepatitis B, will be presented. FOCUS: Gilead Commitment to Collaboration and Public Health The FOCUS program is a public health initiative that enables partners to develop and share best practices in routine blood-borne virus (HIV, HCV, HBV) screening, diagnosis and linkage to care. Two presentations will underscore how innovative approaches and strategic partnerships are driving measurable progress to help combat viral hepatitis and HIV. Dr. Su Wang, from Cooperman Barnabas Medical Center, will present a model for resilient public health infrastructure through an automated electronic medical record (EMR)-based screening program. The initiative demonstrates how health systems can leverage technology to maintain robust monitoring systems, identify individuals with viral infections and offer linkage to care. This approach exemplifies how local action can help sustain national public health priorities in the face of potential decreases in federal funding. Meanwhile, the Kentucky Department for Public Health will share results from a pilot program that introduced point-of-care HCV RNA testing in community settings serving people who use drugs and those experiencing homelessness. By integrating rapid diagnostics into routine care, the initiative highlights how targeted implementation can help remove systemic barriers, accelerate linkage to care, and improve health equity for vulnerable populations. Together, these efforts reflect the transformative potential of data-driven strategies and public-private collaboration in advancing public health goals and strengthening public health systems. Gilead Commitment to Advocacy At The Liver Meeting®2025, Gilead will launch Reflecting Realities™, a campaign dedicated to capturing the emotions and real experiences of people living with liver conditions. Reflecting Realities™ brings together two campaigns: “BehinD the SilenCe” in collaboration with the World Hepatitis Alliance (WHA) and All the Feelings with PBC™ in collaboration with the PBC Foundation and Friends of the PBC Foundation. “BehinD the SilenCe” highlights the experiences of people living with viral hepatitis and will feature portrait photographs of people living with viral hepatitis and audio testimonials of their lived experience. These campaigns aim to showcase the real impact of liver disease and facilitate more meaningful conversations between people living with liver disease and their healthcare providers. Additionally, Gilead will announce which independent emerging investigators Gilead has selected to participate in its Research Scholars Program in PBC. The objective of the program is to support innovative research that aims to close scientific knowledge gaps and address unmet medical needs. For more information, including a complete list of abstract titles being presented at the meeting, please visit the AASLD website. Key Abstracts at AASLD 2025: ID Abstract Title PBC Late-breaker Oral November 10, 2025 5:15 – 5:30 PM Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients with Primary Biliary Cholangitis Treated with Seladelpar: Results from the ASSURE Study up to 30 Months Late-breaker Poster Session November 10, 2025 8:00 AM – 5:00 PM Real-World Experience of Seladelpar Among Patients with Primary Biliary Cholangitis Including Patients Switched from Obeticholic Acid Late-breaker Poster Session November 9, 2025 8:00 AM – 5:00 PM Disease Control as Evidenced by Longitudinal Transient Elastography Measurements in the ASSURE Study: 36 Months of Treatment with Seladelpar is Associated with Stable or Improved Liver Stiffness Abstract #213 Oral November 10, 2025 2:30 – 2:45 PM Seladelpar is Associated with a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients with Primary Biliary Cholangitis Treated up to 48 Months in the Ongoing, Open-Label ASSURE Study Abstract #4471 Poster Session November 10, 2025 8:00 AM – 5:00 PM Improvements in Patient-Reported General Health and Well-Being in Patients with Primary Biliary Cholangitis Treated with Seladelpar in the RESPONSE Trial Abstract #4434 Poster Session November 10, 2025 8:00 AM – 5:00 PM Sustained Efficacy and Safety of Seladelpar for up to 36 Months in Patients with Primary Biliary Cholangitis from the Placebo-Controlled RESPONSE Study to the Open-Label ASSURE Study Abstract #4505 Poster Session November 10, 2025 8:00 AM – 5:00 PM Reduction in Itch-Associated Disability and Pruritus Distribution in Patients with Primary Biliary Cholangitis Treated with Seladelpar in the RESPONSE Trial Abstract #4459 Poster Session November 10, 2025 8:00 AM – 5:00 PM Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis and Elevated Bilirubin at Baseline in the Phase 3 Placebo-Controlled RESPONSE Trial Abstract #4438 Poster Session November 10, 2025 8:00 AM – 5:00 PM Efficacy and Safety of Seladelpar vs. Elafibranor in Patients with Primary Biliary Cholangitis: A Matching-Adjusted Indirect Comparison HDV Abstract #2263 Poster Session November 8, 2025 8:00 AM – 5:00 PM Elevations in Total Serum Bile Acids During Bulevirtide Treatment are Asymptomatic and Not Associated with Adverse Events of Interest in Patients with Chronic Hepatitis Delta Abstract #2245 Poster Session November 8, 2025 8:00 AM – 5:00 PM Persistent Low Viremic Relapse vs High Viremic Relapse After the End of Treatment with Bulevirtide with or Without Pegylated Interferon in Patients with Chronic Hepatitis Delta Virus Abstract #2262 Poster Session November 8, 2025 8:00 AM – 5:00 PM Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants with Severe Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function Abstract #2268 Poster Session November 8, 2025 8:00 AM – 5:00 PM Disease Progression Among Commercially Insured Patients Infected with Hepatitis Delta Virus in the United States Abstract #2254 Poster Session November 8, 2025 8:00 AM – 5:00 PM Integrated Virology Analysis of Bulevirtide (BLV) Monotherapy in Chronic Hepatitis Delta: Pooled Data through 96 Weeks of Treatment HCV Abstract #1380 Poster of Distinction November 7, 2025 8:00 AM – 5:00 PM Cumulative Review of Sofosbuvir/Velpatasvir Exposure in Pregnant Women with Hepatitis C Virus from a Pharmacovigilance Safety Database Abstract #3058 Poster Session November 9, 2025 8:00 AM – 5:00 PM Real-World Implications of the New AASLD/IDSA HCV "Test and Treat" Algorithm: Focus on Cardiovascular Comedications in Hepatitis C Virus (HCV) Patients Receiving Direct-acting Antivirals (DAAs) HBV Abstract #1278 Poster Session November 7, 2025 8:00 AM – 5:00 PM Exposure to Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate and the Risk of Hepatocellular Carcinoma Abstract #1234 Poster Session November 7, 2025 8:00 AM – 5:00 PM Metabolic Comorbidities and the Risk of Liver-Related Events in Individuals with Hepatitis B Virus Infection HBV Cure Abstract #197 Oral November 9, 2025 5:00 – 6:30 PM Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results from a Phase 1b Study in Virally Suppressed Patients with Chronic Hepatitis Abstract #1186 Poster Session November 7, 2025 8:00 AM – 5:00 PM Characterization of HIV/HBV co-infected patients achieving high rates of Hepatitis B Surface Antigen loss in the ALLIANCE Phase 3 clinical study FOCUS Abstract #261 Oral Session November 10, 2025 5:30 PM – 5:45 PM Point-of-Care HCV RNA Testing in Street Medicine: Advancing Patient Engagement and Medicaid Policy in Kentucky, USA Abstract #3017 Poster of Distinction November 9, 2025 8:00 AM – 5:00 PM Automated Screening of Bloodborne Viruses in Health Systems: Regional Model for Syndemic Testing About Livdelzi Livdelzi® is an oral PPAR-delta agonist, or delpar, for the treatment of PBC. PPAR-delta has been shown to regulate critical metabolic and liver disease pathways. Preclinical and clinical data indicate Livdelzi has anticholestatic, anti-inflammatory, antipruritic, and antifibrotic effects. U.S. Indication for Livdelzi® Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. The FDA approved this indication under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use: Use of Livdelzi is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy). U.S. Important Safety Information for Livdelzi Warnings and Precautions Fractures: Fractures occurred in 4% of LIVDELZI-treated patients compared to no placebo-treated patients. Consider the risk of fracture in the care of patients treated with LIVDELZI and monitor bone health according to current standards of care. Liver Test Abnormalities: LIVDELZI has been associated with dose-related increases in serum transaminase (AST and ALT) levels > 3 x ULN in patients receiving 50 mg and 200 mg once daily (5x and 20x higher than the recommended dosage of 10 mg once daily). Perform baseline clinical and laboratory testing when starting LIVDELZI and monitor thereafter according to routine patient management. Interrupt treatment if the liver tests (ALT, AST, total bilirubin, and/or ALP) worsen, or if the patient develops signs and symptoms of clinical hepatitis (eg, jaundice, right upper quadrant pain, eosinophilia). Consider permanent discontinuation if liver tests worsen after restarting LIVDELZI. Biliary Obstruction: Avoid use of LIVDELZI in patients with complete biliary obstruction. If biliary obstruction is suspected, interrupt LIVDELZI and treat as clinically indicated. Adverse Reactions The most common adverse reactions (≥5%) with LIVDELZI were headache (8%), abdominal pain (7%), nausea (6%), abdominal distension (6%), and dizziness (5%). Drug Interactions OAT3 Inhibitors and Strong CYP2C9 Inhibitors: Avoid coadministration with LIVDELZI due to increased LIVDELZI exposure. Rifampin: Monitor biochemical response (e.g., ALP and bilirubin) when patients initiate rifampin during LIVDELZI treatment. Coadministration may result in delayed or suboptimal biochemical response of LIVDELZI. Dual Moderate CYP2C9 and Moderate-to-Strong CYP3A4 Inhibitors and BCRP Inhibitors (eg, cyclosporine): Monitor closely for adverse effects. Concomitant administration with LIVDELZI may increase LIVDELZI exposure. CYP2C9 Poor Metabolizers Using Moderate-to-Strong CYP3A4 Inhibitors: Monitor more frequently for adverse reactions as concomitant use of a moderate-to-strong CYP3A4 inhibitor in patients who are CYP2C9 poor metabolizers may increase LIVDELZI exposure and risk of LIVDELZI adverse reactions. Bile Acid Sequestrants: Administer LIVDELZI at least 4 hours before or 4 hours after taking a bile acid sequestrant, or at as great an interval as possible. Pregnancy and Lactation Pregnancy: There are insufficient data from human pregnancies exposed to LIVDELZI to allow an assessment of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Gilead Sciences, Inc., at 1-800-445-3235. Lactation: There are no data on the presence of LIVDELZI in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LIVDELZI and any potential adverse effects on the breastfed infant from LIVDELZI. Marketing Authorizations In July 2023, the European Commission (EC) granted full Marketing Authorization (MA) for Hepcludex® (bulevirtide) 2 mg for the treatment of adults with chronic HDV and compensated liver disease. Bulevirtide was initially granted a conditional MA from the EC in July 2020 to provide people living with HDV urgent access to treatment. Bulevirtide’s conditional MA license in the UK was converted to a full MA in August 2023, and a full MA was granted in Switzerland in February 2024, in Australia in July 2024 and in Canada in August 2025. In regions where bulevirtide is not approved, including the U.S., bulevirtide 2 mg is an investigational product. In these regions, health authorities have not established the safety and efficacy of bulevirtide. Bulevirtide 10 mg is not approved anywhere globally. A Biologics License Application (BLA) for bulevirtide 10 mg was submitted to the U.S. Food and Drug Administration (FDA) on September 22, 2025, and is pending regulatory decision. In the U.S., Livdelzi® obtained accelerated approval for the treatment of PBC by the U.S. Food and Drug Administration (FDA) in August 2024. Livdelzi received Breakthrough Therapy Designation, as well as Orphan Drug Designation for the treatment of people living with PBC. As part of the FDA accelerated approval, Gilead has committed to AFFIRM, a long-term outcomes study, which has begun in people with compensated cirrhosis. Continued U.S. approval may be contingent upon verification of clinical benefit in confirmatory trial(s). Regulatory review for Livdelzi is underway in Australia and Switzerland. Livdelzi received conditional marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January 2025. In February 2025, the European Commission (EC) granted conditional marketing authorization for Lyvdelzi® (seladelpar) for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. In October 2025, Lyvdelzi received conditional marketing authorization in Canada for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA. About Gilead Sciences in Liver Disease For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. The company has helped to transform hepatitis C from a chronic condition into a curable condition. For individuals living with hepatitis B or hepatitis delta, Gilead's focus on advancing medicines drives hope that today’s research will turn into tomorrow’s cures. Beyond viral hepatitis, Gilead is working to deliver advanced treatments for people living with PBC. The commitment of Gilead does not stop there. Through ground-breaking science and collaborative partnerships, the company strives to create healthier futures for everyone living with liver disease. Gilead remains devoted to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Livdelzi/Lyvdelzi (seladelpar), bulevirtide, tenofovir alafenamide and tenofovir disoproxil fumarate (such as the ALLIANCE, ASSURE, RESPONSE, MYR204, MYR301 and any confirmatory studies); uncertainties relating to regulatory applications and related filing and approval timelines, including additional pending and potential applications for seladelpar and bulevirtide; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Hepcludex, Livdelzi, Lyvdelzi, All the Feelings with PBC, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. U.S. full Prescribing Information for Livdelzi® is available at www.gilead.com. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences) Blair Baumwell, Media public_affairs@gilead.com Jacquie Ross, Investors investor_relations@gilead.com

Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance greater than 32.0%)Announcement today of the proposed acquisition of ImCheck Therapeutics bringing a first-in-class Phase II asset, expanding pipeline in oncology PARIS, FRANCE, 22 October 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025. YTD 2025 YTD 2024 % change Q3 2025 Q3 2024 % change €m €m Actual CER €m €m Actual CER Oncology 1,912.0 1,829.8 4.5 % 6.6 % 624.0 604.0 3.3 % 7.0 % Rare Disease 255.4 129.7 97.0 % 101.0 % 102.0 50.8 100.8 % 109.1 % Neuroscience 567.3 536.4 5.8 % 9.5 % 188.9 181.9 3.9 % 9.1 % Total Sales 2,734.8 2,495.9 9.6 % 12.1 % 915.0 836.6 9.4 % 13.7 % “We have demonstrated strong momentum through the first nine months of 2025, with solid growth across all three therapeutic areas and increasing contributions from our rare liver disease franchise. As a result, we are further upgrading our full-year guidance to reflect this performance." said David Loew, Chief Executive Officer, Ipsen."This quarter, we were also pleased with the data from the Phase II LANTIC trial in aesthetics, with a differentiated first-in-class long-acting molecule, IPN10200. With the proposed acquisition of ImCheck Therapeutics announced this morning, we are adding a first-in-class asset to expand our oncology pipeline. Our efforts remain focused on advancing science with purpose to bring the benefits patients are looking for, as we believe everyone deserves a life fully lived.” Full-year 2025 guidanceBased on the strong performance in the third quarter, Ipsen further upgrades its financial guidance for 2025: Total sales growth of around 10.0%, at CER (prior guidance greater than 7.0%). Based on the average level of exchange rates in September 2025, an adverse impact on total sales of around 3% from currencies is expectedCore operating margin of around 35.0% of total sales (prior guidance greater than 32.0%) This guidance assumes a limited impact from lanreotide generic on Somatuline® sales and an accelerated sales growth from the rest of the portfolio. Pipeline update for Q3 2025On 22 September 2025 Ipsen announced that the LANTIC Phase II trial in aesthetics delivered a first-in-class, differentiated long-acting clinical profile for IPN10200, a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action. Data showed a rapid onset of action, peak effect superior to placebo and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport®, defined as a score of “none” or “mild” of line severity at Week 24. The data will be presented at an upcoming scientific conference in H1 2026, and Phase III start-up activities have been initiated. On 19 September 2025 Ipsen announced regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC) in Japan, offering a non-surgical treatment option for infants, young children and adults. On 23 July 2025, Ipsen received European Commission approval for Cabometyx® (cabozantinib) in previously treated advanced neuroendocrine tumors (NETs), based on positive outcomes from the Phase III CABINET trial. Business developmentOn 22 October 2025 Ipsen announced a definitive share purchase agreement to acquire ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. The acquisition is focused on the lead Phase I/II program ICT01 in first line unfit acute myeloid leukemia (AML) with a Phase IIb/III to start in 2026. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, and which has received Orphan Drug Designation from the U.S. Food and Drug Administration and Orphan designation from the European Medicines Agency in July 2025. Under the terms of the agreement, shareholders of ImCheck Therapeutics will receive a €350m cash payment at closing of the transaction, and deferred payments contingent upon the achievement of specified regulatory approvals and sales-based milestones. The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions. Conference callA conference call and webcast for investors and analysts will begin today at 1pm CET. Participants can access the call and its details by registering here; webcast details can be found here. CalendarIpsen intends to publish its full-year and fourth-quarter results on 12 February 2026. NotesAll financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2025 (YTD 2025) and the three-month period to 30 September 2025 (Q3 2025), compared to the nine-month period to 30 September 2024 (YTD 2024) and the three-month period to 30 September 2024 (Q3 2024), respectively, unless stated otherwise. Commentary is based on the performance YTD 2025, unless stated otherwise. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com - +33 7 64 47 11 49 Khalid Deojee khalid.deojee@ipsen.com - +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com - +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com - +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com. 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 Based on the average level of exchange rates in September 2025, an adverse impact on total sales of around 3% from currencies is expected. Attachment Ipsen PR_YTD 2025 Results Announcement_22102025